🇺🇸 FDA
Pipeline program

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

LOXO-ENC-23001

Phase 1 other active

Quick answer

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors for Advanced/metastatic solid tumor is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Advanced/metastatic solid tumor
Phase
Phase 1
Modality
other
Status
active

Clinical trials